The FDA's regulation of peptides has undergone significant changes in recent years, reshaping how peptide therapies are manufactured, prescribed, and accessed in the United States. Understanding the current regulatory framework is essential for researchers, clinicians, and patients navigating the evolving peptide landscape in 2026.
FDA Regulatory Framework for Peptides
Peptides fall under multiple regulatory categories depending on their intended use, size, and method of production. The FDA regulates peptides through several overlapping frameworks:
- Prescription drugs: FDA-approved peptide drugs (e.g., semaglutide, tesamorelin) go through the full NDA/BLA approval process
- Compounded medications: Peptides compounded under Section 503A (individual prescriptions) or 503B (outsourcing facilities)
- Research chemicals: Peptides sold for research purposes only, not for human consumption
- Dietary supplements: Certain amino acid-based peptides regulated under DSHEA
Key FDA Actions Affecting Peptides (2023-2026)
| Action | Date | Impact |
|---|---|---|
| Category 2 bulk substance nominations | 2023-2024 | FDA evaluated peptides for compounding eligibility |
| GLP-1 agonist compounding restrictions | 2024 | Tightened rules around semaglutide and tirzepatide compounding |
| Updated 503B outsourcing facility inspections | 2024-2025 | Increased scrutiny on peptide compounding quality |
| Bulk drug substance category reviews | 2025-2026 | Ongoing review of which peptides can be compounded |
The Bulk Drug Substance Categories
The FDA uses a three-category system to evaluate substances for compounding:
Category 1 — Approved for Compounding
Substances with adequate safety and usage data. These can be compounded by pharmacies under 503A and 503B regulations. Many traditional peptides fall into this category.
Category 2 — Under Evaluation
Substances nominated for compounding but still under FDA review. The FDA evaluates safety, clinical need, and whether an approved alternative exists. Many newer peptides are in this category.
Category 3 — Not Eligible for Compounding
Substances the FDA has determined should not be compounded, typically due to safety concerns or the availability of approved alternatives. Placement in Category 3 effectively restricts access.
Peptides Affected by Recent FDA Actions
| Peptide | Current Status | Key Consideration |
|---|---|---|
| BPC-157 | Under review (Category 2) | No FDA-approved version exists; compounding eligibility uncertain |
| Semaglutide | FDA-approved (Ozempic/Wegovy); compounding restricted during shortage | Compounding only allowed during active FDA shortage designation |
| Tirzepatide | FDA-approved (Mounjaro/Zepbound); similar restrictions | Compounding subject to shortage status |
| PT-141 (Bremelanotide) | FDA-approved (Vyleesi); compounding limited | Approved version available limits compounding justification |
| CJC-1295 | Under review | No FDA-approved version; compounding eligibility being evaluated |
| Ipamorelin | Under review | Popular in anti-aging clinics; regulatory future uncertain |
What This Means for Patients
Prescription Peptides
FDA-approved peptides (semaglutide, tirzepatide, tesamorelin) remain available through standard prescriptions. Insurance coverage varies but is expanding for approved indications.
Compounded Peptides
Access to compounded peptides depends on the specific peptide's regulatory category and whether an FDA-approved version exists. Working with a licensed compounding pharmacy that operates under either 503A or 503B frameworks is essential.
Research Peptides
Peptides sold as "research chemicals" or "not for human consumption" exist in a legal gray area. While purchasing for legitimate research is legal, self-administration is not sanctioned by the FDA.
Frequently Asked Questions
Are peptides legal in the United States?
Peptides occupy various legal categories in the US. FDA-approved peptide drugs (like semaglutide) are fully legal with a prescription. Compounded peptides are legal when prepared by licensed pharmacies under 503A or 503B regulations for patients with valid prescriptions. Research peptides can be legally purchased for legitimate research purposes. The legality depends on the specific peptide, its regulatory status, and the intended use.
Can I still get BPC-157 prescribed?
BPC-157's prescribing status depends on its ongoing FDA category review. As of 2026, it remains in the evaluation process. Some compounding pharmacies may still prepare BPC-157 under 503A or 503B regulations, but availability varies by state and pharmacy. Consulting with a physician who specializes in peptide therapy is the best way to determine current access options in your area.
Why is the FDA restricting peptide compounding?
The FDA's primary concerns include patient safety (ensuring compounded peptides meet quality standards), the availability of FDA-approved alternatives (reducing the need for compounding), and preventing the marketing of unapproved drugs as compounded medications. The FDA argues that its approval process ensures safety and efficacy in ways that compounding oversight cannot fully replicate.
Conclusion
The FDA's peptide regulatory landscape continues to evolve as the agency evaluates individual compounds for compounding eligibility while maintaining the availability of approved peptide drugs. Staying informed about regulatory changes is essential for anyone involved in peptide therapy — whether as a prescriber, pharmacist, or patient.